CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO AUGUST 2021 * Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, bu

CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO AUGUST 2021

* Forward-Looking Statements This presentation contains forward-looking statements about PDS

Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market

opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words "anticipates," "may," "can," "plans," "believes," "estimates," "expects," "projects," "intends,"

"likely," "will," "should," "to be," and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and

uncertainties that could cause actual results to differ materially from those anticipated.Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption "Risk

Factors" in the documents filed with the Securities and Exchange Commission ("SEC") from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place

undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements

included in this presentation to reflect subsequent events or circumstances.

* PDS Biotech's Versamune -based immunotherapies are designed to promote a powerful in vivo

tumor-specific CD8+ killer T-cell response Generate the right type and quantity of effective CD8+ killer T-cells Generate potency without systemic side effects Generate memory T-cells, to enhance durability of response A significant

barrier to effective immunotherapy has been the inability to promote adequate CD8+ killer T-cell responses in vivo70-90% of cancer patients fail check point inhibitor therapy Versamune -based therapies also show promising potential to:

PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on

the proprietary Versamune platform * Interim data from NCI-led PDS0101 Phase 2 trial showed tumor reduction in ~70% of patients who had failed prior treatmentNo new or elevated toxicities observed from the addition of PDS0101 to

combination therapyPre-clinical studies demonstrate potency and versatility of Versamune in oncology and infectious diseaseMultiple composition and application patents valid through mid-2030s Biopharma developing novel T-cell activating

cancer treatment candidates Three phase 2 oncology clinical trials in progress with multiple near-term readoutsClinical partnerships with Merck, MD Anderson Cancer Center and National Cancer Institute18 employees with headquarters in Florham

Park, NJDebt free with approximately $29.5M in cash* as of June 7, 2021 PIPELINE VERSAMUNE PLATFORM CORPORATE OVERVIEW *The Company received $4.5M from the sale of NJ Net Operating Loss Tax Benefits in May 2021 which has been added

to the cash balance reported on our Form 10-Q as of 3/31/2021.

PDS Biotech executive team has demonstrated success in the development and commercialization of leading

pharmaceutical products * Senior executive experience with management of strategy and execution at both large pharma and biotechsNotable drug development:Abelcet (Liposome Company/ Elan)PEG-Intron (Schering-Plough/ Merck) Frank

Bedu-Addo, PhDChief Executive Officer Co-founder>35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing Gregory Conn, PhDChief Scientific Officer >30 years

of translational clinical research experienceFormer Director of Clinical Research at National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) Lauren V. Wood, MDChief Medical Officer Senior executive experience with

over 20 years of experience in high tech companiesIn-depth experience with M&A transactions, capital markets, business development and investor relations Seth Van Voorhees, PhDChief Financial Officer

PDS Biotech's robust Versamune -based pipeline is being developed in partnership with leaders in

immuno-oncology and infectious disease * Reference: Data on file. * *Consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquimica. Funding provided by The Ministry of Science, Technology and Innovation of Brazil ("MCTI")

Introduction to PDS0101

* Approximately 43,000 patients are diagnosed with HPV-associated cancers annually in the US

alone1Cancers caused by HPV include anal, cervical, head and neck, penile vaginal and vulvar cancersIncidence rate of HPV-related head and neck and anal cancer is growing and remains a significant unmet medical needExisting immunotherapies

cost $120,000+ annually per patient References: Markowitz et al. 2016. Centers for Disease Control and Prevention. 2018. Hernandez et al. 2018. American Journal of Managed Care Volume 24, Issue 2; Company Research, Strauss J. et al. 2021

ASCO Annual Meeting Abstract: 2501. PDS0101 is designed to treat advanced human papillomavirus (HPV)-16 cancers which represents 70-80% of the HPV-associated cancer market

Sub-cutaneous injection of PDS0101 monotherapy induced high quantity of potent HPV16-specific

CD8+T-cells in Phase 1 clinical trial * 2-4 Patient 2-5 3-1 3-2 5-7 2-7 High HLA Type A2 A2 A3 A74 A2 HPV-specific T-cell ResponseIFN- ELISPOT Patient 5-1 5-4 2-1 2-3 Low Medium HLA Type A2 A1, A2, A3,

30 HPV-specific T-cell ResponseIFN- ELISPOT Responses were evaluated on Days 14-19 after SC injection Predominant CD8+ T-cell responses confirmed by Granzyme-b ELISPOT Pre-treatment Post-treatment Lesion

regression in 8/10 CIN patients within 3 months of treatment (Retrospective analysis)No recurrence within 2-year evaluation period may suggest durable immune responses *

Phase 2 NCI-led clinical trial evaluating the triple combination of PDS0101, Bintrafusp alfa and M9241

in advanced HPV-associated cancer * Indication Patients with advanced HPV-associated cancer who have failed prior treatment Clinical Agents Bintrafusp alfa: Bifunctional checkpoint inhibitor-"TGF- trap" fusion proteinM9241:

Antibody-conjugated immuno-cytokinePDS0101: Versamune -based immunotherapy generating HPV-specific CD8+ T-cells Study goals Group 1: Objective response rate (ORR) in checkpoint inhibitor (CPI) na ve patientsGroup 2: ORR in patients who have

failed checkpoint inhibitor therapy (CPI refractory) Timing Full enrollment of 56 patientsComplete enrollment expected by Q1 2022 Trial Sponsor The objective of this trial is to evaluate the potential of the triple combination to

provide an effective therapy for patients with advanced and untreatable cancer

Percentages of HPV-related cancers (anal, cervical, head and neck, vaginal and vulvar cancers) included

in the interim data study population PDS0101 interim Phase 2 trial data presented by the NCI at ASCO 2021: Most HPV-associated cancers are represented - >95% of all US cases * Cervical(40%) Anal(24%) Vaginal/Vulvar(12%) Head &

Neck(24%) Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual

Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation

ASCO 2021: PDS0101 triple combination achieved 83% ORR among six advanced HPV16-positive CPI naive

patients, suggesting potential efficacy * Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of

Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients at a median of 8 months; numbers will change as more patients undergo evaluation

ASCO 2021: Triple combination achieved 58% tumor reduction among 12 HPV16 checkpoint inhibitor

refractory patients * Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021

Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients at a median of 8 months; numbers will change as more patients undergo evaluation 5 patients had already achieved an

objective response (>30% tumor reduction)

* ASCO 2021: Triple combination shows promising durability of the anti-cancer efficacy in

HPV16-positive checkpoint inhibitor na ve patients PDS0101 + Bintrafusp alfa + M9241 Standard of Care(Checkpoint Inhibitors) HPV16-positive Number of checkpoint inhibitor na ve patients 6 Ongoing objective responses at median of

8 months 80% (4/5) Survival at median of 8 months 100% (6/6) Historical is 7-11 months Number of checkpoint inhibitor refractory patients 12 Ongoing tumor reduction at median of 8 months 86% (6/7) Ongoing objective responses at

median of 8 months 80% (4/5) Survival at median of 8 months 83% (10/12) Historical is 3-4 months Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16

positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. Preliminary results suggest PDS0101 induction of in vivo highly active tumor-attacking HPV16 killer

(CD8+) T-cells even in extensively treated and immunologically limited patients have the potential for effective disease reduction and ongoing responses * These numbers reflect data as of evaluation of 25 patients; numbers will change as

more patients undergo evaluation

ASCO 2021: Results in HPV16-negative patients suggests critical role of PDS0101-induced HPV16-specific

CD8+ T-cells in promoting tumor reduction * Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of

Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation Preliminary results suggest that

HPV16-specific CD8+ and CD4+ T-cell induction by PDS0101 as predicted by preclinical studies may promote enhanced clinical benefit of the triple combination

* Phase 2 trial evaluating the combination of PDS0101/KEYTRUDA for treatment of HPV16-positive

metastatic/recurrent head and neck cancer (VERSATILE-002) Indication Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread or returned Clinical Agents KEYTRUDA (Standard of Care): Anti-PD1 checkpoint

inhibitor (ORR ~20%)PDS0101: Versamune -based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Group 1: Objective response rate (ORR) as first-line treatment in checkpoint inhibitor (CPI) na ve patientsGroup 2: ORR in

patients who have failed checkpoint inhibitor therapy (CPI refractory) Timing Preliminary data anticipated Q4 2021/Q1 2022 Trial Partner Confirmation that PDS0101 enhances the therapeutic benefit of checkpoint inhibitors could expand

evaluation of Versamune -based therapies in multiple cancer indications

* Phase 2 investigator-led trial evaluating the combination of PDS0101 and chemoradiation in patients

with locally advanced cervical cancer (IMMUNOCERV) Indication Treatment of patients with locally advanced cervical cancer - Stages IB3-IVA Clinical Agents Chemoradiotherapy (CRT - Standard of Care): Cisplatin and radiation therapyPDS0101:

Versamune -based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Safety, rate of regression and local control in patients with primary tumor 5cm (n=35 patients) Timing Preliminary data anticipated 1H 2022 - Rate

of complete response by PET-CT at 6 months and rate of tumor volume reduction by MRI at 30-40 days from start of treatment Trial Sponsor If successful, this study could support further investigation of Versamune -based immunotherapies in

combination with chemotherapy or CRT to treat multiple cancers

Development of PDS0102

* * Approximately 470,000 patients are diagnosed annually with AML, prostate or breast cancer, most

of which are associated with target T-cell receptor gamma alternate reading frame protein (TARP) Acute Myeloid Leukemia (AML)Almost 20,000 cases in the US annuallyTARP expressed in 100% of AML Prostate cancerAlmost 175,000 US cases

annuallyThe immunogenic TARP protein is expressed in about 90% of prostate cancers at all stages of the disease^Breast cancerMore than 270,000 US cases annuallyTARP expressed in about 50% of breast cancers at all stages of the

disease References: Fritzche FR et al. Histol Histopathol 2010 Jun; 25 (6): 733-9 doi: 10.14670/HH-25.733, Cancer Facts & Figures, American Cancer Society, 2019, LV Wood, et al. Oncoimmunology, 2016. Vol 5. No 8. e1197459. Prostate

Cancer (174,650) Breast Cancer (271,270) AML(19,970) PDS0102 is designed to treat cancers caused by T-cell receptor gamma alternate reading frame protein (TARP), including AML, prostate and breast cancers

* * PDS0102 may provide superior induction of TARP-specific tumor attacking CD8+ killer

T-cells Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8)CFA - Complete Freund's Adjuvant a highly potent immune activator not used in humans due to potentially lethal toxicity PRE-CLINICAL OPTIMIZATION STUDIES: TARP-Specific

T-cell Induction after 2 injections of PDS0102

Development of PDS0103

Clinical trial design will seek to evaluate PDS0103 in tumor types with the highest expression of MUC1

and the greatest differences in MUC1 expression between malignant and healthy tissue PDS0103 is designed to treat cancers caused by mucin-1 (MUC1), which is highly expressed in solid tumors and is associated with poor prognosis Reference:

M. Uhlen, et al. A pathology atlas of the human cancer transcriptome. Science.18 Aug 2017. MUC1 protein expression overview data available from https://www.proteinatlas.org/ENSG00000185499-MUC1/tissue.

* * Greater quantity and quality of Versamune -induced CD8+ killer T-cells may result in ability to

eradicate MUC1-positive tumors Induced a >10-fold number of polyfunctional MUC1 specific CD8+ T-cells *Adjuvant = cytokine GMCSFReferences: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model with other immunotherapies reported

in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, September 25, 27 (42): 5906.

PDS0101 Near-Term Milestones and Market Opportunities

Projected milestones through 2022* *Based on current enrollment and forecast modeling as of August

2021. Subject to change. 4Q22 3Q22 2Q22 1Q22 4Q21 3Q21 2Q21 1Q21 Preliminary efficacy data from advanced HPV-associated cancer trial (NCI) Interim data from HPV-associated cancer trial (NCI) Preliminary data from ImmunoCerv (MD

Anderson) expected Preliminary data from VERSATILE-002 (KEYTRUDA combo) expected Expected completion of HPV-associated cancer trial (NCI) * PDS Biotech Funded Clinical Trials Partner Co-Funded Clinical Trials Planned

initiation of Phase 1/2 clinical trial in TARP-related cancers Planned initiation of Phase 1/2 clinical trial in MUC1-related cancers

PDS Biotech's robust Versamune -based oncology pipeline is being developed in partnership with the

leaders in immuno-oncology * Reference: Data on file.

Versamune is designed to induce a robust and targeted anti-tumor response in vivo when administered

with a tumor-associated antigen * References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol.

202 (12): 3524-3536. Smalley Rumfield C et al. 2020. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. for ImmunoTherapy of Cancer 8:e000612. Promotes uptake of vaccine or immunotherapy and entry into lymph

nodes Promotes antigen processing and presentation to T-cells via MHC I and II pathways Activates Type I Interferon pathway, enabling a powerful anti-tumor killer CD8+ T-cell response Versamune + Tumor-associated proteins (antigens)

Greater quantity and quality of Versamune -induced killer T-cells may result in unique ability to

eradicate HPV-positive tumors after a single dose * Induced a >10-fold number of highly potent T-cells and eradication of HPV-positive tumors after a single dose in preclinical studies Single treatment dose Results typical of current